Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.

Ming ZhaoStephen ScottKurt W EvansErkan YucaTurcin SaridoganXiaofeng ZhengHeping WangAnil KorkutChristian X Cruz-PicoMehmet DemirhanBryce KirbyScott KopetzIrmina DialaAlshad S LalaniSarina Piha-PaulFunda Meric-Bernstam

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Taken together, our results provide strong preclinical evidence for combining neratinib with CDK4/6, mTOR, and MEK inhibitors for the treatment of HER2+ cancer.

Keyphrases

papillary thyroid
squamous cell
cell cycle
cell proliferation
lymph node metastasis
stem cells
positive breast cancer
young adults